Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:ADMA NASDAQ:MLYS NASDAQ:RLAY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.77+0.3%$3.77$1.16▼$4.89$665.48M0.762.09 million shs309,239 shsADMAADMA Biologics$10.06-1.9%$12.39$7.21▼$23.98$2.40B0.835.09 million shs3.18 million shsMLYSMineralys Therapeutics$30.26+3.3%$27.14$12.59▼$47.65$2.49B0.491.21 million shs338,835 shsRLAYRelay Therapeutics$12.57-3.3%$11.96$2.67▼$17.32$2.40B1.742.76 million shs1.29 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+7.71%+12.56%+13.10%+34.18%+271.09%ADMAADMA Biologics-2.57%-5.96%+11.53%-37.84%-56.77%MLYSMineralys Therapeutics+0.07%+13.09%+8.57%-4.38%+87.33%RLAYRelay Therapeutics+2.20%-0.23%+3.67%+53.12%+291.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.77+0.3%$3.77$1.16▼$4.89$665.48M0.762.09 million shs309,239 shsADMAADMA Biologics$10.06-1.9%$12.39$7.21▼$23.98$2.40B0.835.09 million shs3.18 million shsMLYSMineralys Therapeutics$30.26+3.3%$27.14$12.59▼$47.65$2.49B0.491.21 million shs338,835 shsRLAYRelay Therapeutics$12.57-3.3%$11.96$2.67▼$17.32$2.40B1.742.76 million shs1.29 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+7.71%+12.56%+13.10%+34.18%+271.09%ADMAADMA Biologics-2.57%-5.96%+11.53%-37.84%-56.77%MLYSMineralys Therapeutics+0.07%+13.09%+8.57%-4.38%+87.33%RLAYRelay Therapeutics+2.20%-0.23%+3.67%+53.12%+291.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.00Buy$11.00130.85% UpsideADMAADMA Biologics 2.83Moderate Buy$25.67155.21% UpsideMLYSMineralys Therapeutics 2.67Moderate Buy$49.1462.42% UpsideRLAYRelay Therapeutics 2.82Moderate Buy$20.5663.57% UpsideCurrent Analyst Ratings BreakdownLatest ACRS, RLAY, ADMA, and MLYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026ACRSAclaris Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $11.005/5/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/4/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/29/2026ACRSAclaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $10.004/29/2026RLAYRelay Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $25.004/28/2026RLAYRelay Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$14.00 ➝ $18.004/28/2026RLAYRelay Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$17.00 ➝ $21.004/28/2026RLAYRelay Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $22.004/28/2026RLAYRelay Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/28/2026RLAYRelay Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$17.00 ➝ $19.004/27/2026MLYSMineralys Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$7.83M84.99N/AN/A$0.85 per share5.61ADMAADMA Biologics$510.17M4.69$0.64 per share15.76$2.01 per share5.00MLYSMineralys TherapeuticsN/AN/AN/AN/A$8.17 per shareN/ARLAYRelay Therapeutics$15.35M156.65N/AN/A$3.27 per share3.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.53N/AN/AN/A-829.58%-52.04%-35.91%5/6/2026 (Estimated)ADMAADMA Biologics$146.93M$0.6016.767.51N/A28.80%37.52%27.87%5/6/2026 (Estimated)MLYSMineralys Therapeutics-$154.65M-$2.37N/AN/AN/AN/A-32.94%-31.68%5/6/2026 (Estimated)RLAYRelay Therapeutics-$276.48M-$1.62N/AN/AN/AN/A-43.17%-39.22%N/ALatest ACRS, RLAY, ADMA, and MLYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ACRSAclaris Therapeutics-$0.16N/AN/AN/A$1.24 millionN/A5/6/2026Q1 2026ADMAADMA Biologics$0.1933N/AN/AN/A$139.98 millionN/A5/6/2026Q1 2026MLYSMineralys Therapeutics-$0.51N/AN/AN/AN/AN/A5/5/2026Q1 2026RLAYRelay Therapeutics-$0.35-$0.41-$0.06-$0.41$5.58 million$3.00 million3/12/2026Q4 2025MLYSMineralys Therapeutics-$0.57-$0.40+$0.17-$0.40N/AN/A2/26/2026Q4 2025ACRSAclaris Therapeutics-$0.15-$0.1614-$0.0114-$0.16$2.07 million$1.30 million2/26/2026Q4 2025RLAYRelay Therapeutics-$0.38-$0.32+$0.06-$0.32$4.34 million$7.00 million2/25/2026Q4 2025ADMAADMA Biologics$0.20$0.20N/A$0.20$139.80 million$139.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AADMAADMA BiologicsN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A3.363.36ADMAADMA Biologics0.166.713.74MLYSMineralys TherapeuticsN/A43.7643.76RLAYRelay TherapeuticsN/A22.6122.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%ADMAADMA Biologics75.68%MLYSMineralys Therapeutics84.46%RLAYRelay Therapeutics96.98%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.60%ADMAADMA Biologics3.90%MLYSMineralys Therapeutics18.94%RLAYRelay Therapeutics4.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million131.84 millionOptionableADMAADMA Biologics530238.16 million228.87 millionOptionableMLYSMineralys Therapeutics2882.45 million66.84 millionOptionableRLAYRelay Therapeutics330191.34 million183.07 millionOptionableACRS, RLAY, ADMA, and MLYS HeadlinesRecent News About These Companies142,228 Shares in Relay Therapeutics, Inc. $RLAY Bought by Sanctuary Advisors LLCMay 6 at 5:00 AM | marketbeat.comRelay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue EstimatesMay 5 at 7:10 PM | zacks.comRelay Therapeutics (NASDAQ:RLAY) Releases Earnings Results, Misses Estimates By $0.06 EPSMay 5 at 6:23 PM | marketbeat.comRelay Therapeutics Reports First Quarter 2026 Financial Results and Corporate UpdatesMay 5 at 4:05 PM | globenewswire.comRelay Therapeutics Q1 2026 earnings previewMay 4 at 6:16 PM | msn.comBuy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash RunwaysMay 4 at 11:07 AM | 247wallst.comRelay Therapeutics Advances Zovegalisib To Phase 3 As Valuation Gap PersistsMay 2, 2026 | finance.yahoo.comRelay Therapeutics (NASDAQ:RLAY) Insider Sells $11,136.87 in StockMay 1, 2026 | insidertrades.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Rating of "Moderate Buy" from AnalystsMay 1, 2026 | americanbankingnews.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Rating of "Moderate Buy" by AnalystsMay 1, 2026 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Insider Sells $11,136.87 in StockApril 30, 2026 | marketbeat.comThomas Catinazzo Sells 972 Shares of Relay Therapeutics (NASDAQ:RLAY) StockApril 30, 2026 | marketbeat.comInsider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells 1,490 Shares of StockApril 30, 2026 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Short Interest UpdateApril 29, 2026 | marketbeat.comRelay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026April 29, 2026 | globenewswire.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 7.9% - Here's WhyApril 28, 2026 | marketbeat.comCitizens Jmp Raises Relay Therapeutics (NASDAQ:RLAY) Price Target to $19.00April 28, 2026 | marketbeat.comRelay Therapeutics Unveils Zovegalisib Triplet Data, Signs Pfizer Supply Deal for Phase III PlanApril 28, 2026 | marketbeat.comRelay Therapeutics, Inc. (RLAY) Discusses Zovegalisib Triplet Data and First-Line Breast Cancer Strategy TranscriptApril 27, 2026 | seekingalpha.comRelay Therapeutics, Inc. (RLAY) Discusses Zovegalisib Triplet Data and First-Line Breast Cancer Strategy - SlideshowApril 27, 2026 | seekingalpha.comRelay Therapeutics (RLAY) Expected to Announce Earnings on MondayApril 27, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 2026Broadcom Hits $2 Trillion Market Cap as Google Reveals New AI ChipsBy Leo Miller | April 28, 2026ACRS, RLAY, ADMA, and MLYS Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$4.76 +0.02 (+0.32%) As of 12:44 PM Eastern This is a fair market value price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.ADMA Biologics NASDAQ:ADMA$10.06 -0.19 (-1.88%) As of 12:45 PM Eastern This is a fair market value price provided by Massive. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Mineralys Therapeutics NASDAQ:MLYS$30.26 +0.98 (+3.33%) As of 12:45 PM Eastern This is a fair market value price provided by Massive. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Relay Therapeutics NASDAQ:RLAY$12.57 -0.43 (-3.33%) As of 12:45 PM Eastern This is a fair market value price provided by Massive. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
